title: Ivacaftor: a review of its use in patients with cystic fibrosis.
abstract: Ivacaftor (Kalydeco™) is a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) and is the first drug that treats an underlying cause of cystic fibrosis to be licensed for use. Ivacaftor increases the open probability (i.e. gating) of CFTR channels with the G551D mutation, thus enhancing chloride transport, and is indicated in a number of countries for the treatment of cystic fibrosis in patients aged ≥6 years who carry this mutation. This review focuses on pharmacological, clinical efficacy and tolerability data relevant to the use of ivacaftor in this indication. In two 48-week, double-blind, phase III trials in patients aged ≥12 (STRIVE) or 6-11 (ENVISION) years with cystic fibrosis and the G551D mutation, oral ivacaftor 150 mg every 12 h significantly improved lung function relative to placebo, when used in combination with standard care. Significant improvements in pulmonary exacerbation risk (in STRIVE) as well as bodyweight and some aspects of health-related quality of life (both studies) were also seen with the drug versus placebo. Moreover, the beneficial effects of ivacaftor on parameters such as lung function and bodyweight were maintained over up to 96 weeks of treatment in an ongoing open-label extension of these studies. Ivacaftor was generally well tolerated, with headache, oropharyngeal pain, upper respiratory tract infection and nasal congestion being among the most common adverse events. Thus, ivacaftor expands the current treatment options for patients with cystic fibrosis who have the G551D mutation. Its potential for use in patients with other CFTR mutations is also of interest.
authors.affiliation: Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand, demail@springer.com.
authors.forename: Emma D
authors.initials: ED
authors.lastname: Deeks
mesh_terms: D000627:Aminophenols / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000627:Aminophenols; D015363:Quinolones; C545203:ivacaftor
references.citation: Am J Respir Crit Care Med. 2013 Jun 1;187(11):1219-25
references.pmid: 23590265
references.citation: J Pediatr Gastroenterol Nutr. 2002 Sep;35(3):246-59
references.pmid: 12352509
references.citation: Am J Respir Crit Care Med. 2013 Apr 1;187(7):680-9
references.pmid: 23540878
references.citation: J Biol Chem. 2012 Oct 26;287(44):36639-49
references.pmid: 22942289
references.citation: Ann Pharmacother. 2012 Jul-Aug;46(7-8):1065-75
references.pmid: 22739718
references.citation: N Engl J Med. 2011 Nov 3;365(18):1663-72
references.pmid: 22047557
references.citation: Arch Immunol Ther Exp (Warsz). 2011 Apr;59(2):97-112
references.pmid: 21311988
references.citation: Chest. 2011 Jun;139(6):1480-1490
references.pmid: 21652558
references.citation: Lancet. 2009 May 30;373(9678):1891-904
references.pmid: 19403164
references.citation: JAMA Otolaryngol Head Neck Surg. 2013 Aug 1;139(8):822-7
references.pmid: 23949358
references.citation: Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4404-9
references.pmid: 23440202
references.citation: N Engl J Med. 2010 Nov 18;363(21):1991-2003
references.pmid: 21083385
references.citation: Chest. 2012 Sep;142(3):718-724
references.pmid: 22383668
references.citation: J Cyst Fibros. 2008 May;7(3):179-96
references.pmid: 18456578
references.citation: J Cyst Fibros. 2011 Jul;10(4):258-64
references.pmid: 21458391
references.citation: Respir Care. 2009 May;54(5):595-605
references.pmid: 19393104
references.citation: J Cyst Fibros. 2014 Jan;13(1):29-36
references.pmid: 23891399
references.citation: J Cyst Fibros. 2012 May;11(3):237-45
references.pmid: 22293084
references.citation: Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18825-30
references.pmid: 19846789